Enhanced Melanoma Vaccine Against Neoantigens and Shared Antigens by CD40 Activation and TLR Agonists
Abstract
This project will test the hypotheses that vaccination with CD40 Ab/polyICLC will be safe and will induce strong and durable T cell responses to the peptides in the vaccine, and that a mutated neoantigen peptide (BRAF585-614V60E)will be immunogenic and will support infiltration and regression of BRAF-mutant nevi. We also hypothesize that the vaccine regimen will activate DC and induce tertiary lymphoid structures in the vaccine-site microenvironment. This will be accomplished through a clinical trial (NCT04364230). All approvals are in place. We expect to open to enrollment in September or October 2020.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2020
- Accession Number
- AD1117667
Entities
People
- Timothy Bullock
Organizations
- University of Virginia